eyesmart.com.au

Bausch + Lomb announced that the U.S. Food and Drug Administration (FDA) has approved the company's New Drug Application (NDA) for PROLENSA™ (bromfenac ophthalmic solution) 0.07 percent prescription eye drop, an innovative once-daily nonsteroidal anti-inflammatory drug (NSAID) for the treatment of postoperative inflammation and reduction of ocular pain in patients who have undergone cataract surgery. PROLENSA will be available in 1.6ml and 3ml bottle sizes. PROLENSA provides powerful and rapid resolution of inflammation and pain by leveraging the unique potency of the bromfenac molecule in a formulation designed to facilitate ocular penetration. The advanced formulation allows for a lower concentration of bromfenac in a once daily dosing regimen. PROLENSA is a solution that does not require shaking to deliver a consistent dose in each drop.

The efficacy of PROLENSA was evaluated in two randomized, double-masked, vehicle-controlled studies of patients undergoing cataract surgery. Each randomized patient received PROLENSA or vehicle starting with one drop into the surgical eye on the day prior to and the day of surgery, and for 14 days following surgery. The primary efficacy endpoint was complete clearing of ocular inflammation (assessed by the summed ocular inflammation score, SOIS, which includes cells and flare) by day 15. The secondary efficacy endpoint was the number of subjects that were pain free on day one after surgery.

Results from the pivotal studies demonstrated PROLENSA to be superior to vehicle in the treatment of both inflammation and pain following cataract surgery. Twice as many patients as vehicle (46 percent versus 20 percent) demonstrated complete clearance of inflammation (SOIS of 0) at day 15. The difference in the average post-operative inflammation severity between the treatment and vehicle arms was statistically and clinically significant by day eight. Nearly four of five patients treated with PROLENSA were pain free at day one (78.8 percent versus 49.5 percent for vehicle; p<0.0001). Patients treated with PROLENSA reported a lower incidence of foreign body sensation and photophobia and had less redness than those treated with vehicle.

The U.S. Food and Drug Administration (FDA) has cleared to market myVisionTrack™, a prescription-only medical device that enables patients with retinal diseases to monitor their vision function between regular visits to their eye-care professional to help ensure they obtain timely care and treatments.

Using a proprietary patented shape discrimination hyperacuity (SDH) test, myVisionTrack™ enables patients to regularly assess their vision function. The device stores test results, tracks disease progression and automatically alerts a health care provider if it suspects significant deterioration of visual function in the patient.

Age-related macular degeneration (AMD), diabetic retinopathy (DR) and other retinal diseases afflict more than 40 million people in countries with advanced health care systems. Roughly 13 million people suffer from these diseases in the United States. During the past decade, new therapies have been developed for these degenerative eye diseases, but timely diagnosis and treatment are critical to their effectiveness.

Clinical studies demonstrate that myVisionTrack™'s shape discrimination hyperacuity test has comparable or higher sensitivity and specificity as compared to clinically available standard visual function tests for detecting advanced maculopathy from high-risk moderate maculopathy.

myVisionTrack™ can be used in a physician's office or at home by patients with maculopathy to help track disease progression, detect disease condition changes for earlier intervention and document treatment effects. Research confirms high satisfaction and compliance rates among patients able and willing to self-test at home with myVisionTrack™.

More information about myVisionTrack™ can be found at www.myvisiontrack.com.

After a very successful launch and distribution of the Cosmo metal collection in 2012, Benner is proud to unveil Cosmo Duo this spring. One of the most unique features of the Cosmo collection is the huge variety of colour combinations. Combining a base colour with a top colour and selecting the effect how this top-colour is painted, all Cosmo styles offer a wide range of looks from discreet to funky just by choosing a more calm or original colour combination.

The colour variety that can be chosen for every style plus the great adjustability were the design-base when creating Cosmo Duo. But now with the addition of an extra material: Acetate!

Cellulose acetate parts were connected to a fine metal "skeleton" using a nylon wire. This gives the frame sturdiness and flexibility at the same time. The metal part of the frames come in the same seven colours like the metal Cosmos, the acetate comes in three colours. Also there's a choice of having a mat or a shiny surface for the acetate rings.

Combining all these option it comes to a choice of 42 different combinations and again, through the very wearable shapes the styles range from calm to funky, just by choosing the colour of the metal and acetate parts.Like the metal Cosmo collection, the full frame is completely made in Germany near Stuttgart.

The launch of the new collection at the recently held Vision Expo East has received great attention.